Predictive biomarkers for drug response in bladder cancer

Bladder cancer is a heterogeneous disease. Interpatient heterogeneity in response to a drug limits treatment options and impairs improvement of patient survival. For example, approximately half of patients do not respond to cisplatin‐based combination chemotherapy, although it is the standard of car...

Full description

Saved in:
Bibliographic Details
Published in:International journal of urology 2019-11, Vol.26 (11), p.1044-1053
Main Authors: Yoshida, Takahiro, Kates, Max, Fujita, Kazutoshi, Bivalacqua, Trinity J, McConkey, David J
Format: Article
Language:English
Subjects:
Biomarkers
Bladder cancer
Cancer
Cancer therapies
Chemotherapy
Cisplatin
DNA damage
DNA repair
drug response
Health risk assessment
Immune checkpoint inhibitors
Immunosuppressive agents
Invasiveness
Metastases
neoadjuvant chemotherapy
Organoids
predictive biomarker
Tumors
urothelial cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bladder cancer is a heterogeneous disease. Interpatient heterogeneity in response to a drug limits treatment options and impairs improvement of patient survival. For example, approximately half of patients do not respond to cisplatin‐based combination chemotherapy, although it is the standard of care for muscle‐invasive and metastatic bladder cancer. The development of robust predictive biomarkers is expected to improve outcomes by enabling clinicians to use chemotherapy only in the patients who will benefit from it. Recent advances in the molecular characterization of bladder cancer showed that the basal subtype of bladder cancer and tumors with inactivating mutations in DNA damage repair genes were associated with greater benefit from cisplatin‐based chemotherapy. The present review summarizes current efforts to develop predictive biomarkers for drug response in bladder cancer, focusing on those that predict the response to cisplatin‐based chemotherapy for advanced bladder cancer. We also review the current situation with regard to the identification of predictive biomarkers for response to intravesical therapy, immune checkpoint inhibitors and molecularly‐targeted drugs. We also discuss the future applications of new technologies, including liquid biopsies and patient‐derived organoids that will also serve as resources for the identification of biomarkers in bladder cancer.
ISSN:0919-8172
1442-2042
DOI:10.1111/iju.14082